Prothena presents TDP-43 data at neuroscience conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
November 19, 2025 4:05 PM ESTTDP-43 CYTOPE® preclinical data demonstrates the potential of Prothenas CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular disease pathways Systemically-administered TDP-43 CYTOPE rapidly and efficiently distributed to the brain and periphery, internalized into the cytosol and significantly reduced intracellular TDP-43 pathology in an ALS mouse model TDP-43 CYTOPE meaningfully reduced intracellular TDP-43 pathology and associated RNA dysregulation caused by cryptic exon inclusions - key pathogenic features of TDP-43 proteinopathies - in a human-derived neuronal cell line
Â
DUBLIN, Ireland--(BUSINESS WIRE)-- Prothena... More
